CHA Biotech said it has signed a memorandum of understanding (MOU) with Sartorius Korea Biotech, the Korean subsidiary of the global bioprocessing company Sartorius, to establish Korea’s first mesenchymal stem cell platform and develop automated 3D mass-production technology capable of scaling beyond 50 liters.

Through the partnership, the two companies aim to secure large-scale production technologies essential for the development and commercialization of stem cell therapies that meet global standards.

Their joint efforts will include building a globally compliant stem cell line platform, automating 3D manufacturing processes at scales over 50 liters, developing standardized and advanced production protocols, and establishing a mass-production platform for next-generation stem cell therapies enhanced with therapeutic genes.

By combining their core strengths, CHA Biotech and Sartorius plan to maximize the efficiency and cost-effectiveness of stem cell culture and accelerate the path to commercialization.

CHA Biotech, in collaboration with CHA University’s Institute for Stem Cell and Regenerative Medicine, operates an integrated R&D system that spans from basic research to clinical development.

The company is currently establishing globally compliant stem cell lines that meet regulatory requirements in the U.S., Europe, and Japan.

Based on this foundation, CHA Biotech is advancing a pipeline of cell therapies, including candidates for ovarian insufficiency, knee cartilage defects, and gingival recession.

It is also building a platform to mass-produce next-generation stem cell therapies incorporating therapeutic genes to expand into the global market.

Sartorius, a world leader in cell manufacturing and culture technologies, provides state-of-the-art equipment, media, and raw materials for bioprocessing.

Its technologies are expected to play a critical role in enhancing the stability and efficiency of large-scale stem cell manufacturing processes.

“This collaboration will create strong synergies by combining CHA Biotech’s unrivaled expertise in stem cell research with Sartorius’ process technologies,” Sartorius Korea Biotech CEO Kim Duck-sang said. “Together, we will deliver innovative stem cell therapy production solutions and strengthen competitiveness in the global market.”

CHA Biotech R&D head Nam Su-yeon also said, “Through this partnership with Sartorius, we can address the technical challenges of large-scale stem cell manufacturing and accelerate the development of globally competitive therapies.”

The company looks forward to continuing this collaboration to lead the stem cell therapy industry, Nam added.